Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Udo Holtick

Showing results (61-70 of 95) with videos related to

Pageof 10
Sort By:
European Journal of Cancer (Oxford, England : 1990)|December 7, 2014
Phase I clinical study of the toll-like receptor 9 agonist MGN1703 in patients with metastatic solid tumoursMartin R Weihrauch, Heike Richly, Michael S von Bergwelt-Baildon, et al.
Journal of Immunology (Baltimore, Md. : 1950)|October 15, 2014
Inhibition of protein geranylgeranylation specifically interferes with CD40-dependent B cell activation, resulting in a reduced capacity to induce T cell immunityAlexander Shimabukuro-Vornhagen, Shahram Zoghi, Tanja M Liebig, et al.
European Journal of Haematology|May 22, 2021
Selective ABO immunoadsorption in hematopoietic stem cell transplantation with major ABO incompatibilityMartina Crysandt, Hatice Soysal, Eva Jennes, et al.
Viruses|September 23, 2020
RNAemia Corresponds to Disease Severity and Antibody Response in Hospitalized COVID-19 PatientsKirsten Alexandra Eberhardt, Charlotte Meyer-Schwickerath, Eva Heger, et al.
Haematologica|June 1, 2023
Azacitidine, lenalidomide and donor lymphocyte infusions for relapse of myelodysplastic syndrome, acute myeloid leukemia and chronic myelomonocytic leukemia after allogeneic transplant: the Azalena-TrialThomas Schroeder, Matthias Stelljes, Maximilian Christopeit, et al.
Journal of Clinical Medicine|January 11, 2024
Multiparametric Monitoring of Disease Progression in Contemporary Patients with Wild-Type Transthyretin Amyloid Cardiomyopathy Initiating Tafamidis TreatmentSvenja Ney, Roman Johannes Gertz, Lenhard Pennig, et al.
Hemasphere|June 18, 2026
Teclistamab in relapsed/refractory light chain amyloidosis: A retrospective multicenter study by the German Society for Amyloid DiseasesAlexander Carpinteiro, Christoph Kimmich, Despina Trajanova, et al.
Transplantation and Cellular Therapy|September 14, 2023
Long-Term Survivors after Failure of Chimeric Antigen Receptor T Cell Therapy for Large B Cell Lymphoma: A Role for Allogeneic Hematopoietic Cell Transplantation? A German Lymphoma Alliance and German Registry for Stem Cell Transplantation AnalysisPatrick Derigs, Wolfgang A Bethge, Isabelle Krämer, et al.
Blood|March 23, 2006
Long-term survival in refractory acute myeloid leukemia after sequential treatment with chemotherapy and reduced-intensity conditioning for allogeneic stem cell transplantationChristoph Schmid, Michael Schleuning, Rainer Schwerdtfeger, et al.
Transplantation and Cellular Therapy|March 17, 2022
High Mortality of COVID-19 Early after Allogeneic Stem Cell Transplantation: A Retrospective Multicenter Analysis on Behalf of the German Cooperative Transplant Study GroupJudith Schaffrath, Christina Brummer, Daniel Wolff, et al.
Pageof 10

Showing results (61-70 of 95) with videos related to

Sort By:
Pageof 10
European Journal of Cancer (Oxford, England : 1990)|December 7, 2014
Phase I clinical study of the toll-like receptor 9 agonist MGN1703 in patients with metastatic solid tumoursMartin R Weihrauch, Heike Richly, Michael S von Bergwelt-Baildon, et al.
Journal of Immunology (Baltimore, Md. : 1950)|October 15, 2014
Inhibition of protein geranylgeranylation specifically interferes with CD40-dependent B cell activation, resulting in a reduced capacity to induce T cell immunityAlexander Shimabukuro-Vornhagen, Shahram Zoghi, Tanja M Liebig, et al.
European Journal of Haematology|May 22, 2021
Selective ABO immunoadsorption in hematopoietic stem cell transplantation with major ABO incompatibilityMartina Crysandt, Hatice Soysal, Eva Jennes, et al.
Viruses|September 23, 2020
RNAemia Corresponds to Disease Severity and Antibody Response in Hospitalized COVID-19 PatientsKirsten Alexandra Eberhardt, Charlotte Meyer-Schwickerath, Eva Heger, et al.
Haematologica|June 1, 2023
Azacitidine, lenalidomide and donor lymphocyte infusions for relapse of myelodysplastic syndrome, acute myeloid leukemia and chronic myelomonocytic leukemia after allogeneic transplant: the Azalena-TrialThomas Schroeder, Matthias Stelljes, Maximilian Christopeit, et al.
Journal of Clinical Medicine|January 11, 2024
Multiparametric Monitoring of Disease Progression in Contemporary Patients with Wild-Type Transthyretin Amyloid Cardiomyopathy Initiating Tafamidis TreatmentSvenja Ney, Roman Johannes Gertz, Lenhard Pennig, et al.
Hemasphere|June 18, 2026
Teclistamab in relapsed/refractory light chain amyloidosis: A retrospective multicenter study by the German Society for Amyloid DiseasesAlexander Carpinteiro, Christoph Kimmich, Despina Trajanova, et al.
Transplantation and Cellular Therapy|September 14, 2023
Long-Term Survivors after Failure of Chimeric Antigen Receptor T Cell Therapy for Large B Cell Lymphoma: A Role for Allogeneic Hematopoietic Cell Transplantation? A German Lymphoma Alliance and German Registry for Stem Cell Transplantation AnalysisPatrick Derigs, Wolfgang A Bethge, Isabelle Krämer, et al.
Blood|March 23, 2006
Long-term survival in refractory acute myeloid leukemia after sequential treatment with chemotherapy and reduced-intensity conditioning for allogeneic stem cell transplantationChristoph Schmid, Michael Schleuning, Rainer Schwerdtfeger, et al.
Transplantation and Cellular Therapy|March 17, 2022
High Mortality of COVID-19 Early after Allogeneic Stem Cell Transplantation: A Retrospective Multicenter Analysis on Behalf of the German Cooperative Transplant Study GroupJudith Schaffrath, Christina Brummer, Daniel Wolff, et al.
Pageof 10